Symbols

INKT

MiNK Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 2

Significant Net Income Decline

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About INKT

Mink Therapeutics, Inc.

A biotechnology company focused on developing cancer immunotherapies and autoimmune disease treatments

Industry

Biological Technology

Established Date

Listing Date

10/15/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.minktherapeutics.com

Security Type

Common stock

Office address

149 Fifth Avenue, Suite 500, New York, NY 10010

Business

Introduction

MiNK Therapeutics, Inc., was incorporated in Delaware in July 2017. The Company is a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf iNKT cell therapies for the treatment of cancer and other immune-mediated diseases. The company is leveraging its platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of natural and engineered iNKT cells with multiple clinical and preclinical readouts expected in 2021 and 2022. The company's strategy is to advance an accessible, scalable and effective cell therapy platform that leverages the innate and durable biological advantages of iNKT cells to optimize scalability and rapid clinical development.

Earnings Call

Q1/2025

Estimate EPS-0.61

Actual EPS-0.7

Estimate Revenue--

Actual Revenue0

MiNK Therapeutics Q1 2025: Contradictions Unraveled on Funding, Trial Timelines, and Data Expectations

May 21,2025 02:24·
Earnings Decrypt

Q2/2025

Estimate EPS-0.55

Actual EPS-1.06

Estimate Revenue--

Actual Revenue0

MiNK Therapeutics Q2 2025: Unraveling Key Contradictions in GvHD and ARDS Trial Strategies

Aug 14,2025 04:26·
Earnings Decrypt

Company Financials

EPS

INKT has released its 2025 Q3 earnings. EPS was reported at -0.65, versus the expected -0.86, beating expectations. The chart below visualizes how INKT has performed over recent quarters, highlighting trends in earnings surprises.